Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.
The in vitro activities of the novel des-fluoro(6) quinolone BMS-284756, ciprofloxacin, gatifloxacin and moxifloxacin were tested against 248 genetically defined Staphylococcus aureus isolates, comprised of 116 unrelated S. aureus, seven heterogeneous vancomycin-intermediate S. aureus (hetero-VISA) strains and 125 clonally related MRSA. All strains were susceptible to BMS-284756 at an investigational breakpoint of 1 mg/L. Reserpine did not decrease the MIC of BMS-284756 in any of the strains tested. The novel des-fluoro(6) quinolone BMS-284756 showed a significantly increased anti-staphylococcal activity.
Schmitz
Franz-Josef
FJ
Institute for Medical Microbiology and Virology, Heinrich-Heine University Düsseldorf, Germany. schmitfj@uni-duesseldorf.de
Boos
Mechthild
M
Mayer
Susanne
S
Jagusch
Harold
H
Fluit
Ad C
AC
D000890:Anti-Infective Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000706:statistics & numerical data; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D024841:Fluoroquinolones; D006801:Humans; D007211:Indoles; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D015363:Quinolones; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin